BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34456923)

  • 1. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.
    Lin P; Gao RZ; Wen R; He Y; Yang H
    Front Immunol; 2021; 12():715460. PubMed ID: 34456923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
    Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
    J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation.
    Liu P; Deng X; Zhou H; Xie J; Kong Y; Zou Y; Yang A; Li X
    Front Immunol; 2023; 14():1297180. PubMed ID: 38022619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
    J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 8. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
    Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
    EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of DNA damage response pathways in hepatocellular carcinoma.
    Yang SF; Chang CW; Wei RJ; Shiue YL; Wang SN; Yeh YT
    Biomed Res Int; 2014; 2014():153867. PubMed ID: 24877058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis.
    Benfeitas R; Bidkhori G; Mukhopadhyay B; Klevstig M; Arif M; Zhang C; Lee S; Cinar R; Nielsen J; Uhlen M; Boren J; Kunos G; Mardinoglu A
    EBioMedicine; 2019 Feb; 40():471-487. PubMed ID: 30606699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.
    Liu T; Wu H; Qi J; Qin C; Zhu Q
    Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma.
    Zhang L; Chen J; Yong J; Qiao L; Xu L; Liu C
    J Exp Clin Cancer Res; 2019 Sep; 38(1):384. PubMed ID: 31477177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma.
    Zhu X; Cheng Y; Wu F; Sun H; Zheng W; Jiang W; Shi J; Ma S; Cao H
    Technol Cancer Res Treat; 2020; 19():1533033820977524. PubMed ID: 33280519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
    Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
    J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
    Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
    J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.